ABUS

Arbutus Biopharma Corp

Add to Watchlist

Advanced Chart

3.080

-0.040(-1.280%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

3.150

Open

3.100

VWAP

3.09

Vol

1.05M

Mkt Cap

589.90M

Low

3.050

Amount

3.26M

EV/EBITDA(TTM)

Total Shares

188.72M

484.86M

EV/OCF(TTM)

P/S(TTM)

95.04

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

1.61M

-6.28%

1.60M

+20.46%

922.77K

-41.18%

Estimates Revision

The market is revising Upward the revenue expectations for Arbutus Biopharma Corporation (ABUS) for FY2025, with the revenue forecasts being adjusted by 22.34% over the past three months. During the same period, the stock price has changed by -8.33%.

Revenue Estimates for FY2025

Revise Upward

+22.34%

In Past 3 Month

Stock Price

Go Down

-8.33%

In Past 3 Month

1 Analyst Rating

62.34% Upside

Wall Street analysts forecast ABUS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABUS is 5.00 USD with a low forecast of 5.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

62.34% Upside

Current: 3.080

Low

5.00

Averages

5.00

High

5.00

62.34% Upside

Current: 3.080

Low

5.00

Averages

5.00

High

5.00

Chardan Capital

Keay Nakae

Strong Buy

Maintains

2025-03-28

Reason

Chardan Capital

Keay Nakae

Price Target

2025-03-28

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Ed Arce

Strong Buy

Reiterates

2025-01-21

Reason

HC Wainwright & Co.

Ed Arce

Price Target

2025-01-21

Reiterates

Strong Buy

Reason

Chardan Capital

Keay Nakae

Strong Buy

Maintains

$4.5 → $5

2024-11-20

Reason

Chardan Capital

Keay Nakae

Price Target

$4.5 → $5

2024-11-20

Maintains

Strong Buy

Reason

Chardan analyst Keay Nakae raised the firm's price target on Arbutus Biopharma to $5 from $4.50 and keeps a Buy rating on the shares. The firm is citing the company's follow-up and end-of-treatment data from the IM-PROVE I Phase 2a and IM-PROVE II Phase 2a clinical trials on imdusiran at AASLD, noting that while the data is from a small sample of patients, the combination therapy regimens evaluated in IM-PROVE I demonstrated a possible best path to proceed down to achieve the goal of functional cure, the analyst tells investors in a research note.

HC Wainwright & Co.

Ed Arce

Strong Buy

Reiterates

2024-11-18

Reason

HC Wainwright & Co.

Ed Arce

Price Target

2024-11-18

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Ed Arce

Strong Buy

Reiterates

2024-11-07

Reason

HC Wainwright & Co.

Ed Arce

Price Target

2024-11-07

Reiterates

Strong Buy

Reason

Chardan Capital

Keay Nakae

Strong Buy

Maintains

$4 → $4.5

2024-11-06

Reason

Chardan Capital

Keay Nakae

Price Target

$4 → $4.5

2024-11-06

Maintains

Strong Buy

Reason

Chardan raised the firm's price target on Arbutus Biopharma to $4.50 from $4 and keeps a Buy rating on the shares after its Q3 results. The firm remains encouraged about the company's lead asset, imdusiran, as an important component in the treatment for chronic hepatitis B, which is expected to require a combination therapy approach, the analyst tells investors in a research note. The cash runway for Arbutus extends into Q4 of 2026, the firm added..

See All Ratings

Valuation Metrics

The current forward P/E ratio for Arbutus Biopharma Corp (ABUS.O) is -16.88, compared to its 5-year average forward P/E of -6.10. For a more detailed relative valuation and DCF analysis to assess Arbutus Biopharma Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.10

Current PE

-16.88

Overvalued PE

-3.11

Undervalued PE

-9.08

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.13

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

3.51

Undervalued EV/EBITDA

-7.77

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Overvalued

5Y Average PS

42.11

Current PS

91.01

Overvalued PS

75.76

Undervalued PS

8.47

Financials

Annual

Quarterly

FY2025Q1

YoY :

+15.14%

1.76M

Total Revenue

FY2025Q1

YoY :

-32.09%

-13.03M

Operating Profit

FY2025Q1

YoY :

-100.00%

N/A

Net Income after Tax

FY2025Q1

YoY :

+30.00%

-0.13

EPS - Diluted

FY2025Q1

YoY :

-30.94%

-13.39M

Free Cash Flow

FY2025Q1

YoY :

-100.00%

N/A

Gross Profit Margin - %

FY2025Q1

N/A

FCF Margin - %

FY2025Q1

YoY :

-100.00%

N/A

Net Margin - %

FY2025Q1

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

251.7K

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

353.6K

Volume

Months

6-9

0.0

Volume

Months

0-12

3.4M

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

251.7K

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

ABUS News & Events

Events Timeline

2025-05-14 (ET)

2025-05-14

07:34:19

Arbutus Biopharma reports Q1 EPS (13c), consensus (15c)

2025-05-07 (ET)

2025-05-07

05:31:46

Arbutus Biopharma presents data from two HBV assets

2025-03-27 (ET)

2025-03-27

07:36:03

Arbutus Biopharma reduced workforce by 57%

News

9.5

05-14SeekingAlpha

PinnedArbutus Biopharma GAAP EPS of -$0.13 misses by $0.03, revenue of $1.76M beats by $0.17M

9.0

05-07Newsfilter

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

9.0

05-07NASDAQ.COM

Arbutus Biopharma Reports Positive Phase 2a Results for Imdusiran in Combination with VTP-300 and Low Dose Nivolumab in Chronic Hepatitis B Patients at EASL 2025